When people hear the word “natural,” they may assume a remedy is automatically harmless. That assumption is not a reliable guide to safety. A product can have a traditional history and still produce an unwanted effect, interact with another medicine, be unsuitable for a particular person, or be advertised with claims that go beyond the evidence. Good medicine safety depends not on dismissing a tradition or praising it uncritically, but on listening carefully, recording what happened, checking the details, and learning from reports.
India’s Ministry of Ayush supports a pharmacovigilance programme for Ayurveda, Siddha, Unani and Homoeopathy medicines. The programme’s public-facing Ayush Suraksha portal describes a system for documenting suspected adverse drug reactions and monitoring objectionable or misleading advertisements. This article explains what that kind of monitoring means, how its national and local network is described, why a report is not the same as proof of cause, and how readers can approach safety information responsibly. It is an educational overview, not medical advice and not an assessment of any individual product.
What pharmacovigilance means
Pharmacovigilance is the organised work of detecting, assessing, understanding and helping to prevent adverse effects and other medicine-related problems. It is often called medicine or drug safety. The idea is broader than looking for a dramatic reaction after a dose. It includes collecting reports, checking whether descriptions are complete, comparing similar events, looking for patterns, communicating findings and, where evidence supports it, considering steps that could reduce harm. The Ministry-supported Ayush Suraksha material describes this work for ASU&H drugs and also includes monitoring of misleading advertisements.
Monitoring continues after products are being used in real life because clinical studies and pre-market review cannot represent every person, pattern of use or combination of treatments. A medicine may be used by people with different ages, health conditions, diets and concurrent medicines. Some events are uncommon; some may only become visible after a long period or across many users. A reporting system therefore adds a channel for learning from experience. It complements, rather than replaces, clinical care, regulatory review, laboratory standards or careful research.
Why “natural” is not a safety test
“Natural” describes an origin or marketing idea, not a complete evaluation of risk. Plants contain biologically active substances; their identity, part used, preparation, dose, storage and quality can matter. A traditional formulation may contain several ingredients. A packaged product may be mislabelled, contaminated, adulterated, substituted, poorly stored or used differently from its directions. Those possibilities do not mean that every traditional medicine is unsafe. They mean that safety should be assessed through evidence and context rather than assumed from a label or a slogan.
Risk also depends on the person and circumstances. A medicine that one person has taken without a problem may not suit another person, particularly where there are other illnesses, pregnancy, allergies or other medicines. This article does not attempt to identify particular interactions or recommend a treatment. It makes a narrower point: when a possible unwanted effect occurs, documenting it can help qualified professionals and safety systems investigate; a reassuring anecdote or a claim of “no side effects” is not a substitute for such assessment.
What counts as an event and what counts as a reaction?
Ayush Suraksha distinguishes an adverse event from an adverse drug reaction. Its reporting page defines an adverse event as an untoward medical occurrence in a patient or clinical-trial subject given a medicinal product, without requiring that the product caused it. The event may be an unfavourable sign, symptom, disease or abnormal laboratory finding that occurs in time with product use. In other words, the report records an occurrence and its timing, not a settled conclusion about why it happened.
The same portal describes an adverse drug reaction as a noxious and unintended response for which a causal relationship with the medicinal product is at least a reasonable possibility. That distinction is important. A person may become ill after taking a product because of the product, an underlying condition, another medicine, an infection, or more than one factor. Timing can be a clue, but it cannot by itself prove causation. Reporting a suspected event lets the system examine it; the report should not be presented as a confirmed finding unless a proper assessment has established that.
Serious events deserve prompt attention
The portal’s ADR-reporting page describes a serious adverse event as one that results in death, is life-threatening, requires hospital admission or prolongs an existing admission, causes persistent or significant disability or incapacity, or involves a congenital anomaly or birth defect. This is a classification used for safety reporting; it is not a prediction that any particular event will have that outcome. The terms help reviewers identify reports that may need particular attention.
If someone is experiencing a severe or rapidly worsening health problem, the priority is urgent care from an appropriate health professional or emergency service, not completing an online report first. A pharmacovigilance form is a record for safety monitoring and does not provide treatment or replace an emergency response. Once immediate care is being addressed, a patient, caregiver or clinician may be able to preserve packaging and treatment details and use the official reporting route. Do not delay care to search for a product’s online listing or to determine on your own whether the medicine caused the event.
A three-tier reporting network
The Ayush Suraksha portal describes a three-tier arrangement: a National Pharmacovigilance Coordination Centre (NPvCC), Intermediary Pharmacovigilance Centres (IPvCs) and Peripheral Pharmacovigilance Centres (PPvCs). The Ministry’s All India Institute of Ayurveda in New Delhi is identified as the national coordinating centre. The portal says reports from across India reach the national centre through intermediary and peripheral centres. The structure is intended to connect local reporting with coordination and analysis at a national level.
In its description of the initial arrangement, the portal identifies five intermediary centres at national Ayush institutes and a network of peripheral centres at institutes, research councils and academic hospitals. Counts shown on the portal and in government reports can vary with the date and scope of the source. For example, the Ayush Suraksha home page and FAQ have described 97 peripheral centres, while a Ministry report excerpt from a later period states that 99 had been established. Such figures should be quoted with their source and date, not blended into one supposedly timeless number. The useful takeaway is the networked model, not a claim that the directory never changes.
From an individual report to a safety signal
A report is one piece of evidence. Reviewers may need to clarify which product was taken, when it was taken, what happened, when symptoms began, what else was being used and whether the patient received care. They may assess whether the sequence is plausible, whether similar reports exist and whether other explanations need consideration. The CCRH annual report for 2023–24 describes the programme’s purpose as collecting, collating and analysing data to build evidence about clinical safety and conducting surveillance of advertisements. It also notes that traditional herbal products can present particular monitoring challenges because naming, perception, sourcing and use may differ.
When multiple reports share a pattern, the pattern may be a signal worthy of further investigation. A signal is not automatically proof that a product caused harm, and absence of a signal is not proof that a product is risk-free. The quality and completeness of information influence what can be learned. Under-reporting, duplicate reports, unclear product identity or missing dates can make patterns difficult to interpret. This is why careful records and cautious language matter. Public summaries should distinguish “reported,” “under review,” “associated” and “caused” rather than treating them as interchangeable.
What information makes a report useful?
For a suspected medicine-related event, a clear account usually needs enough detail for a qualified reviewer to understand the sequence. Relevant details may include the name on the package, manufacturer or batch information if available, formulation and strength, how it was used, approximate dates, the event observed, when it began, what happened afterward and whether medical attention was sought. Information about other medicines or important health circumstances may also help an assessor, but should be shared through the official reporting channel and handled with care because it is personal health information.
Precision is more useful than certainty. If the exact start date is unknown, say that it is approximate. If the package is unavailable, say so instead of guessing the product. Record what was observed and who observed it, separating direct observations from interpretations. A statement such as “rash began the next evening” is a description; “the herb caused an allergy” is a conclusion that may require medical assessment. Keep the packaging, label or a clear photograph where practical, but do not post private medical documents or identifying details publicly. Only submit information through an appropriate official channel.
Who can report, and how to use official routes
The Ayush Suraksha FAQ says healthcare professionals, including doctors, nurses and pharmacists, can report adverse drug reactions. It says patients can report through their physician or a medical faculty member, and advises reporting as soon as a drug or therapy is suspected of producing a negative, unintended effect. It directs suspected ADR reports to designated peripheral and intermediary pharmacovigilance centres across the country. The portal publishes a dedicated reporting area and centre directory; readers should consult the live official portal for current instructions and available forms rather than relying on an old copied form.
The portal lists the National Pharmacovigilance Coordination Centre at the All India Institute of Ayurveda, Gautampuri Awas, Sarita Vihar, New Delhi, Delhi 110076. Its listed contact is ayush-pharmavig[at]aiia[dot]gov[dot]in and 011-29948660. Because official contact details and forms can change, verify them on the live contact page before sending information. Do not send sensitive patient details to an address found in an unverified social-media post or advertisement. If unsure which centre to use, ask a registered practitioner or use the official centre directory to locate the appropriate route.
Advertising oversight is a separate safety stream
Medicine safety also depends on what people are told about a product. Ayush Suraksha includes an objectionable or misleading advertisement reporting function. The portal describes surveillance of advertisements in print and electronic media and a public complaint form. This work is related to patient safety because unsupported claims can influence decisions, encourage people to delay care or suggest that a product has official approval when it does not. A report about an advertisement is different from an ADR report: the first concerns a communication or claim; the second records a suspected health event.
When considering an advertisement, preserve the exact wording, date, platform and a link or screenshot if lawful and safe to do so. Distinguish the statement actually made from your interpretation of it. Do not publicly accuse a named person or company of a crime based only on a promotional post. The Ministry’s 2024 advisory notes that the Ministry does not grant manufacturing licences or approvals for Ayush medicines and warns manufacturers against claims such as “100% safe,” “free from side effects,” “guaranteed treatment,” “permanent cure,” or “approved/certified by Ministry of Ayush.” A reader can report concerns through the official reporting route without treating an allegation as a proven violation.
What official approval does and does not mean
The Ministry’s 18 April 2024 advisory explains that licences for Ayurveda, Siddha and Unani drugs are issued by State Drug Licensing Authorities under the Drugs and Cosmetics Act and Rules, and that such state licensing should not be described as Ministry of Ayush approval. The advisory also refers to specific labelling provisions in the Drugs and Cosmetics Rules and to laws governing drug advertisements, including the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. These are the Ministry’s stated regulatory points; this article is not a legal opinion about any particular label or advertisement.
A licensing or compliance statement should be described narrowly and accurately. It should not be converted into a claim that a product is guaranteed to work, suitable for everyone, free of adverse effects or endorsed by a ministry. Conversely, a disputed advertisement is not by itself a final legal finding against its maker. Readers can look for a product’s complete label and manufacturer details, consult a qualified practitioner and verify claims using official sources. Any decision about compliance belongs to the competent authority applying the relevant law and evidence.
Labelling, identity and quality are part of the evidence
A report can be difficult to interpret if the product itself cannot be identified. The brand name may be similar to another, the formulation may have changed, or a label may not show the information a reporter needs. A clear package photograph can preserve spelling, ingredients as printed, manufacturer details, batch number, expiry date and instructions. These details may help identify the item and trace it through a quality process. A label is evidence of what the package says; it does not independently prove that contents match the label or that a product is safe for a particular person.
The Ministry’s broader quality work includes standards development and drug-testing capacity. A government report describes PCIM&H as a Ministry subordinate office that develops pharmacopoeial standards for ASU&H drugs and functions as a central drug testing and appellate laboratory for these systems. Standards and testing can support product identity and quality, while pharmacovigilance addresses suspected effects during use. These functions complement one another but are not interchangeable: a quality standard does not answer every question about clinical use, and a report of an unwanted effect does not automatically establish a manufacturing defect.
Careful communication about uncertainty
Responsible reporting uses language that matches what is known. “A reaction was reported after use” states sequence and source. “The product caused the reaction” asserts causality and should be reserved for a suitably assessed conclusion. “No reactions were reported in this source” describes that source’s records, not every user or every period. “No risk exists” is a much broader claim and is rarely supported by a limited dataset. The same care applies to advertising: quote claims accurately, preserve context and avoid amplifying a questionable promise without explaining that it is under review.
When a report is incomplete, it should remain incomplete in the account rather than being filled with assumptions. If a product name, date or outcome cannot be confirmed, state that plainly. If two official sources show different counts, include the publication dates and explain that the figures represent different snapshots. These habits make a safety article more transparent and help readers understand that monitoring is an ongoing process, not a one-time certificate of certainty.
Privacy and respectful handling of reports
Health information is sensitive. A public article should not reproduce a patient’s name, phone number, address, medical record number, identifiable photograph or private correspondence. A reporting form may ask for personal details so assessors can seek clarification; provide those details only through the official form and according to its privacy notice. In public discussion, use a de-identified example only when there is a legitimate reason and enough context to prevent re-identification. Consent and data minimisation are especially important when the patient is a child or another person who cannot meaningfully manage disclosure.
Respectful language also matters. People who report symptoms should not be mocked as unreliable, and practitioners should not be accused of misconduct without evidence. A report documents a concern; it is not a verdict on a patient, clinician, tradition or manufacturer. The goal is to improve understanding and reduce preventable harm. Keeping the person’s account intact while avoiding unsupported conclusions helps reviewers assess information fairly and protects public discussion from becoming a contest of anecdotes.
How readers can evaluate safety information
When a product or treatment is discussed online, ask what exactly is being claimed, who is making the claim, what evidence is offered and whether the evidence is relevant to the product and intended use. Look for the product’s full identity rather than a generic phrase such as “herbal formula.” Check whether the source distinguishes traditional use, laboratory findings, clinical research and regulatory status. A testimonial can describe one person’s experience, but it cannot establish a general effect or guarantee the same result for others.
Be wary of guarantees, miracle language, pressure to buy immediately, claims that a product cures many unrelated conditions, or advice to stop prescribed treatment without consulting a qualified professional. The Ministry’s public notice advises against self-diagnosis and self-medication with ASU&H medicines and says that ASU drugs containing Schedule E1 substances require supervision by a registered practitioner of the relevant Ayush system. Those cautions should be applied as the official notice states; this article does not identify any specific product as falling into that category. For personal treatment questions, consult a registered healthcare professional who can consider the whole situation.
Limits of a reporting database
A database is only as informative as the reports it receives and the methods used to review them. Spontaneous reports may not represent every patient or every product use. Some events go unreported; some reports lack information; the same event may be reported more than once; and the number of reports can rise because awareness or access to reporting changed. A count alone does not tell a reader how often an event occurs among all people using a product. Estimating frequency usually requires additional data, such as an appropriate denominator and a robust study design.
For this reason, public-facing safety communication should not compare products by raw report counts unless the comparison is methodologically justified. A rise in reports may be a reason to investigate, not proof of a new danger. A small count may reflect limited use, limited reporting or incomplete capture, not proof of safety. Pharmacovigilance helps generate and assess evidence, but conclusions should take account of uncertainty, alternative explanations, product identity and the quality of follow-up.
How the reporting and research cycle can work
A simple way to understand the cycle is to imagine a clinician receiving a report that a patient experienced an unexpected problem while taking a named medicine. The clinician documents the product and event, provides appropriate care, and submits a suspected reaction report through the designated channel. A centre checks whether essential information is present, may seek clarification and passes data through the network. Reviewers look across reports for patterns and assess whether additional investigation or communication is warranted. If stronger evidence emerges, the relevant authorities can consider proportionate steps under their responsibilities.
This example is illustrative, not a claim that every report follows identical steps or leads to a particular outcome. A report can remain inconclusive; a reviewer may need more information; and a suspected pattern may not be confirmed. Public systems should be evaluated by their actual procedures and published results, not by an imagined guarantee. Readers can help by recording information accurately, using the official route and understanding that making a report supports monitoring but does not ensure a particular finding or remedy.
What the official sources establish
The Ayush Suraksha site describes a Ministry-supported pharmacovigilance programme for ASU&H drugs, with an aim of documenting suspected adverse effects, monitoring safety and surveilling misleading advertisements. It identifies the All India Institute of Ayurveda as the national coordination centre and presents a network of intermediary and peripheral centres. Its reporting materials distinguish adverse events from adverse drug reactions and provide routes for suspected ADR and advertisement reports. The Ministry’s advisory and public notice provide additional information on licensing, promotional claims, self-medication and the supervision required for certain Schedule E1 drugs.
The CCRH annual report for 2023–24 describes the scheme’s objectives and activities in that reporting period, including collection, collation and analysis of safety information and advertisement surveillance. Its figures and the current portal’s figures should be treated as time-specific snapshots. None of these sources turns every possible report into proof of causality, promises a cure, or establishes that a particular product is safe or unsafe. The sources support a clear public lesson: transparent reporting, qualified review, reliable standards and restrained communication are all parts of medicine safety.
Practical takeaways
For patients and caregivers, the most useful steps are to seek appropriate care for health concerns, keep the product packaging where practical, write down what was used and when, and share a suspected reaction with a qualified practitioner or the official reporting network. Do not wait for certainty about cause before asking a professional how to report a suspected event. Do not use a report form as a substitute for medical care, and do not stop or change prescribed treatment based only on a social-media post.
For readers assessing online claims, check the exact wording and source, separate a licence from an endorsement, and be cautious of absolute promises about safety or permanent cures. For publishers and educators, preserve source dates, qualify counts, avoid copying protected text, protect patient privacy and never imply that a report equals a confirmed causal finding. A strong safety culture is built from evidence and humility: it takes people’s experiences seriously without claiming more than the available facts can support.
Sources and further reading
- Ayush Suraksha: About the pharmacovigilance programme
- Ayush Suraksha: Suspected Adverse Drug Reaction reporting
- Ayush Suraksha: Frequently asked questions
- Ayush Suraksha: National Pharmacovigilance Coordination Centre contact
- Ministry of Ayush advisory on labelling provisions, 18 April 2024
- Ministry of Ayush public notice on ASU&H medicines and public caution
- Central Council for Research in Homoeopathy, Annual Report 2023–24
This content is a collection of ancient history,books and various articles and collection of library and news and other post ; all details may not be the same. Readers are requested to verify the information themselves. Readers are not allowed to take any disciplinary action; content is only for educational purposes. If readers do not agree about the contents, they may send a personal comment to my personal email ID: achary.purna@gmail.com
